Glaukos (NYSE:GKOS) Director Marc Stapley Sells 15,000 Shares

Glaukos Corporation (NYSE:GKOS) Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the transaction, the director directly owned 37,449 shares of the company’s stock, valued at $4,782,611.79. The trade was a 28.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Glaukos Trading Up 3.6%

GKOS stock opened at $124.29 on Tuesday. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $161.78. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The firm has a market cap of $7.14 billion, a P/E ratio of -80.71 and a beta of 0.67. The company’s 50-day simple moving average is $111.25 and its 200-day simple moving average is $96.29.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.Glaukos’s revenue for the quarter was up 38.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.28) EPS. As a group, equities analysts forecast that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Institutional Trading of Glaukos

Several large investors have recently bought and sold shares of GKOS. Riverbridge Partners LLC increased its holdings in shares of Glaukos by 41.0% in the third quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after purchasing an additional 165,673 shares during the last quarter. Holocene Advisors LP boosted its stake in Glaukos by 40.1% during the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock worth $108,030,000 after buying an additional 299,118 shares during the last quarter. Baird Financial Group Inc. grew its holdings in Glaukos by 17.7% in the 2nd quarter. Baird Financial Group Inc. now owns 63,379 shares of the medical instruments supplier’s stock valued at $6,546,000 after buying an additional 9,545 shares in the last quarter. State of New Jersey Common Pension Fund D increased its stake in shares of Glaukos by 4.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 19,905 shares of the medical instruments supplier’s stock worth $2,056,000 after acquiring an additional 800 shares during the last quarter. Finally, Divisadero Street Capital Management LP purchased a new position in shares of Glaukos during the 2nd quarter worth $10,514,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on GKOS shares. Needham & Company LLC reissued a “buy” rating and issued a $125.00 price target on shares of Glaukos in a report on Wednesday, January 14th. The Goldman Sachs Group reissued a “buy” rating and set a $138.00 target price on shares of Glaukos in a research note on Friday, January 9th. UBS Group upped their price target on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Truist Financial lifted their price objective on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Wells Fargo & Company increased their target price on Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.38.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.